REFRACTORY FOLLICULAR LYMPHOMA

This study is for people with a slow-growing type of blood cancer called follicular lymphoma that has come back or stopped responding to treatment. Researchers are testing whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults w…

This early-phase study tests a combination of two drugs, ibrutinib and lenalidomide, in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The main goals are to find the safest dose and understand side effects. About 39 participan…

This study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs work together. About 36 adults with specific …

This study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…

This study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…

This early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study aims to find the safest dose and see if the combination can shrink or stabilize the cancer…

This study tests a new drug combination (ALX148, rituximab, and lenalidomide) in people with slow-growing or fast-growing B-cell non-Hodgkin lymphoma that has not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink or eliminate tumors. …

This early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in 22 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see if the combination can shri…

This early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…

This study tests adding an experimental drug called selinexor to the standard chemotherapy R-CHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced …

This early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy) and vorinostat (a targeted therapy)—in 52 adults with certain types of lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of…

This study tests whether adding the experimental drug tazemetostat to a standard two-drug therapy can help people with relapsed or refractory follicular lymphoma live longer without their cancer getting worse. About 555 adults whose lymphoma has returned or no longer responds to …

This study tests a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. The drug works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shrink or disappe…

This study looked at how well and how safely the drug tazemetostat works in adults with a type of blood cancer called follicular lymphoma that has come back or not responded to previous treatments. Participants took tazemetostat pills twice daily. The study aimed to see if the dr…

This early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival s…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…